Acrivon Therapeutics Inc.... (ACRV)
NASDAQ: ACRV
· Real-Time Price · USD
1.36
-0.03 (-2.16%)
At close: Aug 15, 2025, 3:59 PM
1.38
1.10%
After-hours: Aug 15, 2025, 05:51 PM EDT
Acrivon Therapeutics Common Stock Cash Flow Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 |
Net Income | -85.96M | -83.75M | -80.56M | -76.98M | -69M | -64.12M | -60.39M | -50.06M | -44.8M | -36.7M | -31.17M | -26.58M | -19.82M | -14M | -6.78M | -2.44M |
Depreciation & Amortization | 1.03M | 1.06M | 978K | 824K | 706K | 635K | 536K | 512K | 495K | 444K | 364K | 252K | 145K | 67K | 22K | 9K |
Stock-Based Compensation | 15.1M | 14.73M | 14.29M | 13.64M | 13.2M | 12.32M | 11.62M | 10.21M | 7.24M | 4.79M | 2.19M | 844K | 604K | 371K | 331K | 27K |
Other Working Capital | -2.01M | 903K | 6.02M | 4.67M | 4.14M | 3.89M | 4.96M | 2.82M | 3.32M | -391K | -1.29M | -310K | -2.85M | -1.81M | -441K | -278K |
Other Non-Cash Items | -1.43M | -2.58M | -2.82M | -2.46M | -1.3M | -260K | -849K | -877K | -1.07M | -1.09M | 33K | 619K | 635K | 454K | 276K | 18K |
Deferred Income Tax | n/a | n/a | n/a | -186K | -928K | -1.7M | -1.7M | -1.51M | -768K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 434K | 2.4M | 2.44M | 4.49M | 4.17M | 4.76M | 8.14M | 2.11M | 2.56M | -501K | -1.53M | 476K | -1.74M | -1.25M | 213K | 72K |
Operating Cash Flow | -70.83M | -68.12M | -65.67M | -60.67M | -53.16M | -48.37M | -42.64M | -39.63M | -36.34M | -33.06M | -30.12M | -24.39M | -20.18M | -14.36M | -5.94M | -2.31M |
Capital Expenditures | -2.37M | -2.01M | -2.77M | -3.09M | -2.1M | -2.08M | -1.29M | -388K | -814K | -1.78M | -2.17M | -2.05M | -1.63M | -552K | -137K | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -44.69M | n/a | n/a | n/a | 44.69M | n/a | n/a | n/a | n/a |
Purchase of Investments | -75.04M | -194.82M | -202.93M | -184.75M | -202.73M | -67.9M | -56.53M | -140.76M | -167.14M | -167.14M | -150.18M | -49.37M | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | 146.5M | 158.42M | 153.92M | 142.19M | 144.69M | 117.22M | 108.53M | 76.26M | 56.43M | 36.98M | 10.67M | 4.67M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 44.69M | n/a | n/a | n/a | -44.69M | n/a | n/a | n/a | n/a |
Investing Cash Flow | 69.09M | -38.41M | -51.77M | -45.65M | -60.14M | 47.24M | 50.72M | -64.89M | -111.52M | -131.93M | -141.68M | -46.75M | -1.63M | -552K | -137K | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -2.29M | -2.7M | -2.53M | -3.17M | -1.97M | -1.46M | -1.3M | 101.86M | 101.87M | 101.86M | 101.86M | n/a | -10K | 1K | 1K | 1K |
Financial Cash Flow | -2.59M | 120.86M | 121.03M | 119.66M | 121.25M | -1.73M | -1.55M | 102.32M | 102.1M | 101.71M | 101.71M | 99.6M | 99.74M | 99.75M | 99.75M | 1K |
Net Cash Flow | -4.11M | 14.55M | 3.81M | 13.56M | 7.94M | -2.86M | 6.52M | -2.2M | -45.77M | -63.28M | -70.08M | 28.47M | 77.93M | 84.84M | 93.68M | -2.31M |
Free Cash Flow | -73.19M | -70.13M | -68.44M | -63.77M | -55.26M | -50.45M | -43.93M | -40.02M | -37.16M | -34.83M | -32.28M | -26.44M | -21.81M | -14.91M | -6.08M | -2.31M |